

GLAXOSMITHKLINE PLC  
Form 6-K  
October 26, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 26 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Philip Hampton
  - b) Position/status Non-Executive Chairman
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£16.43	2,662.812
n/a (single transaction)	
  - d) Aggregated information
 

Aggregated volume	Price
  - e) Date of the transaction 2016-10-26
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Professor Sir Roy Anderson
  - b) Position/status Independent Non-Executive Director
  - c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£16.43	437.462
n/a (single transaction)	
  - d) Aggregated information  
Aggregated volume Price
  - e) Date of the transaction 2016-10-26
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr Vindi Banga
  - b) Position/status Senior Independent Non-Executive Director
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s)      Volume(s) £16.43      1,749.848 n/a (single transaction)

Aggregated information  
d) Aggregated volume Price

e) Date of the transaction	2016-10-26
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms Stacey Cartwright
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s)      Volume(s) £16.43      323.341
d) Aggregated information	n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2016-10-26
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr Vivienne Cox
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£16.43	323.341
n/a (single transaction)	

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2016-10-26
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms Lynn Elsenhans

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053
- b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
- c) Price(s) and volume(s) Price(s) Volume(s)  
\$40.70 1,131.786  
n/a (single transaction)
- d) Aggregated information  
Aggregated volume Price
- e) Date of the transaction 2016-10-26
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms Judy Lewent
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depository Shares ('ADSs')

ISIN: US37733W1053

	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s)      Volume(s) \$40.70      454.112 n/a (single transaction)
d) Aggregated information	
	Aggregated volume Price
e) Date of the transaction	2016-10-26
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr Urs Rohner
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2016 to 30 September 2016.
b) Nature of the transaction	
c) Price(s) and	Price(s)      Volume(s)

volume(s)	£16.43	399.422
	n/a (single transaction)	

d) Aggregated information  
Aggregated volume Price

e) Date of the transaction 2016-10-26

f) Place of the transaction n/a

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 26, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc